Methods:
We randomly assigned 1,200 patients to an early invasive or selective invasive strategy. The outcomes were the composite of death or myocardial infarction (MI) and its individual components. Risk stratification was performed with the FRISC (Fast Revascularization in InStability in Coronary artery disease) risk score.
Results: At 5-year follow-up, revascularization rates were 81% in the early invasive and 60% in the selective invasive group. Cumulative death or MI rates were 22.3% and 18.1%, respectively (hazard ratio [HR]: 1.29, 95% confidence interval [CI]: 1.00 to 1.66, p = 0.053). No difference was observed in mortality (HR: 1.13, 95% CI: 0.80 to 1.60, p = 0.49) or MI (HR: 1.24, 95% CI: 0.90 to 1.70, p = 0.20). After risk stratification, no benefit of an early invasive strategy was observed in reducing death or spontaneous MI in any of the risk groups.
Conclusions: In patients presenting with NSTE-ACS and elevated troponin T, we could not demonstrate a long-term benefit of an early invasive strategy in reducing death or MI.
INTRODUCTION
The American College of Cardiology (ACC)/American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines recommend an early invasive strategy for patients presenting with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) without life-threatening symptoms but with high-risk features 1, 2 . An early invasive strategy consists of coronary angiography within 24-72 hours, with subsequent revascularization when indicated. This recommendation is supported by meta-analyses showing evidence of an early hazard balanced by a late benefit, resulting in a significant reduction in death or myocardial infarction (MI) [3] [4] [5] .
The Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) trial compared an early invasive with a selective invasive strategy in patients with NSTE-ACS and positive troponin T 6 . The ICTUS trial showed no benefit of the early invasive strategy for the composite of death, MI, or rehospitalization for anginal symptoms at 1-year and 3-year follow-up 6, 7 . For patients stabilized on medical treatment, a Class IIb recommendation was included in the ACC/AHA guidelines for a selective invasive strategy 1 .
The five-year results of the RITA-3 and FRISC II trials both emphasized the importance of long-term outcomes, showing differences in short-term and long-term mortality 8, 9 . Moreover, these studies showed a beneficial effect of the invasive strategy, most apparent in high-risk patients. To investigate the occurrence of late clinical events, we present the 5-year clinical outcomes of death and MI of the ICTUS trial, with additional subgroup analyses by categories of baseline risk.
METHODS

Study design
The design of the Dutch multicenter ICTUS trial has been published previously 6 . In short, 1200 patients with NSTE-ACS and elevated cardiac troponin T were randomized to an early invasive or a selective invasive strategy.
Patients
Patients (age 18-80 years) were eligible if the following criteria were met: symptoms of ischemia that were increasing or occurring at rest, with the last episode occurring <24 hours before randomization; elevated cardiac troponin T level (≥0.03 μg/L); and either ischemic changes as assessed by electrocardiography or a documented history of coronary artery disease. Exclusion criteria were: STelevation MI <48 hours; an indication for reperfusion therapy; hemodynamic instability or overt congestive heart failure; and an increased risk of bleeding. The collection of long-term follow-up was planned in the protocol and approved by the authorized ethics committee. All patients provided written informed consent.
Randomization and study protocol
In the early invasive strategy, patients were scheduled to undergo coronary angiography within 24-48 hours, and revascularization when appropriate. Patients in the selective invasive strategy were medically stabilized, with angiography and revascularization in case of refractory angina, hemodynamic or rhythmic instability, or clinically significant ischemia on the pre-discharge exercise test. Pharmacological treatment consisted of aspirin, clopidogrel, enoxaparin, abciximab during all percutaneous coronary interventions (PCI), and intensive lipid-lowering therapy 6 .
Follow-up
Patients were contacted by telephone after 5 years from randomization. All potential outcome events were recorded; hospitalizations were reviewed for potential outcome events unless there was an unequivocally non-cardiac reason for admission. If a patient could not be contacted, information was obtained from the patients' family, general practitioner, treating cardiologist and hospital records. Follow-up was censored at the date of last telephone contact, or at 5 years, whichever came first. If the patient was lost to follow-up, censoring was done at the date of last clinical follow-up. Information on vital status was obtained from the Dutch national population registry and was verified until September 12, 2008. Cause of death was obtained from the general practitioner and hospital records. Follow-up for mortality was censored at 5 years. If a patient could not be identified in the national registry, censoring was done at the date of last clinical follow-up.
Outcomes
The main outcomes were the composite of death or recurrent MI, death or spontaneous MI, and the individual components death, cardiovascular death, MI, first spontaneous MI, and first procedure-related MI. Cardiovascular death was defined as all-cause death, unless an unequivocal non-cardiovascular cause could be established. Myocardial infarction was defined as documented myocardial necrosis either in the setting of myocardial ischemia (spontaneous MI) or in the setting of PCI or Coronary Artery Bypass Grafting (CABG) (procedure-related MI) following the recommendations of the Consensus Committee for the definition of MI 10 . All new events occurring after previous reported data were adjudicated blinded to treatment allocation by RJdW and PD 7 .
Statistical analysis
Analysis was by intention-to-treat. Cumulative event rates were estimated using the Kaplan-Meier method. Hazard ratios (HR) with 95% confidence intervals were obtained with Cox proportional-hazards models, including treatment strategy as the only covariate.
Prespecified subgroup analyses included gender, and baseline risk according to the FRISC score. All patients were stratified by the FRISC score, being the sum of the following 7 factors present at admission: age ≥65 years, male gender, 
RESULTS
Patients
A total of 604 patients were assigned to the early invasive and 596 patients to the selective invasive strategy (figure 1). Baseline characteristics were well balanced among the 2 groups (table 1). The median duration of initial hospitalization was 6 days in the early invasive and 7 days in the selective invasive strategy, during which 76% and 40 % of patients, respectively, had been revascularized. Five-year cumulative revascularization was 81% in the early invasive and 60% in the selective invasive strategy; CABG was the first procedure in 23% and 25% respectively. Figure 2 shows revascularization over time. 
Discussion
The present analysis confirms and extends our previous reports, as we could not demonstrate that in patients presenting with NSTE-ACS and an elevated troponin T, an early invasive strategy was superior to a selective invasive strategy in reducing 5-year death or MI. In addition, there were no differences in the individual components of the primary outcome. No late effects were observed, with comparable increments in the outcomes death and MI in both treatment groups up to 5-year follow-up.
A slight trend towards an increase in noncardiovascular mortality was observed in the early invasive group, but this difference did not reach statistical significance (p=0.16). In view of Patients who endured a major bleeding during initial hospitalization were at a higher risk for 5-year mortality compared to those who did not (17.2% versus 10.4%, HR 1.81 (95% CI: 0.74-4.43, p=0.19).
Risk stratification
After stratification by the FRISC score, higher death or spontaneous MI rates were observed with increasing risk scores; 9.9% in the low-risk (scores 1-2), 16.8% in the intermediate-risk (scores 3-4) and 32.1% in the high-risk group (scores 5-7). No significant benefit from an early invasive treatment was observed in any of the risk groups; low-risk HR 1.13 (95% CI: 0.57-2.24, p=0.72), intermediate-risk HR 1.06 (95% CI: 0.74-1.52, p=0.74), high-risk HR 1.15 (95% CI: 0.66-2.03, p=0.62) ( figure 5A ). For illustrative purposes, figure 5B shows Kaplan-Meier curves after stratification using cut-off scores as defined in the long-term results of the FRISC II trial 9 . The low-risk group (scores 0-1) is not shown, including only 3.7% of all patients. The intermediate-risk group includes 57.5% and the high-risk group 38.8% of all patients. Again, no benefit was observed with an early invasive strategy: low-risk HR 0.52 (95% CI: 0.09-2.81, p=0.44), intermediate-risk HR 0.90 (95% CI: 0.57-1.42, p=0.66), high-risk HR 1.27 (95% CI: 0.89-1.82, p=0.20).
invasive strategy is primarily driven by an early increase in procedure-related MIs and this trend towards higher late non-cardiovascular mortality. 
DISCUSSION
A slight trend towards an increase in noncardiovascular mortality was observed in the early invasive group, but this difference did not reach statistical significance (p=0.16). In view of the lack of a biological rationale for this difference between the two treatment groups, this finding is likely the result of the play of chance. Consequently, the slightly higher hazard for death or MI at 5 years associated with the early invasive strategy is primarily driven by an early increase in procedurerelated MIs and this trend towards higher late non-cardiovascular mortality.
Previous NSTE-ACS strategy trials with long-term follow up
The result from our study show important differences when compared with the 5-year outcomes of the RITA-3 and FRISC II trials 8, 9 . In the FRISC II study, mortality was significantly different at 2-year but not at 5-year follow-up. In the RITA-3 study, no difference in mortality was observed at 2-year but a difference was shown at 5-year follow-up. In ICTUS, there was no difference in mortality, neither at 2-years nor at 5-year follow up.
We observed no overall difference in MI between the two strategy groups at 5 years, although procedure-related MIs were slightly more frequent in the early invasive group.
In the RITA-3 and FRISC II trials, the greatest benefit of an invasive strategy was seen in high-risk patients. Remarkably, after risk stratification by the FRISC score, we found no interaction between treatment strategy and risk group. This is unlikely due to a predominance of low-risk patients being included in the ICTUS trial. Applying the FRISC II definition of risk groups, the percentage of patients in the intermediaterisk and high-risk groups in the ICTUS trial (58% and 39% respectively) are higher compared to those of the FRISC II trial (53% and 30% respectively) 9 .
The explanation for diverging results between the three trials is likely multifactorial. The trials were done in different time periods, and there were differences in clinical practice such as the use of stents, GPIIb/IIIa inhibitors, and long term anti-platelet agents and statin treatment. One other possible explanation may be the heterogeneity in the intensity of revascularization over time. In the ICTUS trial, the percentage of revascularized patients at 1-year follow-up was 79% in the early invasive and 54% in the selective invasive group, whereas in the RITA-3 and FRISC II trials, these percentages were 57% and 28%, and 78% and 44% respectively. Therefore, the relatively high intensity of revascularization in the selective invasive arm in ICTUS may be important in explaining the differences in results.
Study limitations
Procedure-related MIs were analyzed mainly during intial hospitalization. Therefore, this could penalize the early invasive arm because other potential MIs as the result of new revascularizations, likely more common in the selective invasive arm, would have gone unnoticed. Procedure-related MIs as documented by hospital records were available up to 5-year follow-up, but routine serial sampling of cardiac biomarkers after PCI in patients without procedure-related complications or clinical symptoms was not available. For our current analysis, we included procedurerelated MIs according to the universal definition of MI 10 . Secondly, in accordance with the FRISC-II and RITA-3 long-term follow-up, we limited our 5-year follow up to death or MI. We observed no differences in rehospitalization for anginal complaints and pharmacological treatment at 2.7 years 7 .
CONCLUSION
In patients presenting with NSTE-ACS and an elevated troponin T, we could not demonstrate a benefit of an early invasive strategy in reducing death or MI at 5 years compared to a selective invasive strategy. After risk stratification by the FRISC score, again no benefit from an early invasive strategy was observed. Although many may prefer an early invasive strategy in patients with NSTE-ACS and high-risk features, a selective invasive strategy may be an attractive alternative in medically stabilized patients. 
